Applicant, as named in the Orange Book

Cubist Pharms Llc

Next listed expiry: Dificid on 31 Jan 2028. 5 products with live protection, 0 without.

Products with listed protection

Drug	Ingredient	NDA	Earliest generic entry	Basis
Dificid fidaxomicin	fidaxomicin	201699	31 Jan 2028	patent
Sivextro tedizolid phosphate	tedizolid phosphate	205435	31 Dec 2030	patent
Sivextro tedizolid phosphate	tedizolid phosphate	205436	31 Dec 2030	patent
Dificid fidaxomicin	fidaxomicin	213138	28 Nov 2034	patent
Zerbaxa ceftolozane sulfate; tazobactam sodium	ceftolozane sulfate; tazobactam sodium	206829	14 Feb 2036	patent